VBI Vaccines (VBIV) Issues Earnings Results, Misses Estimates By $0.02 EPS

Share on StockTwits

VBI Vaccines (NASDAQ:VBIV) issued its earnings results on Friday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02), MarketWatch Earnings reports. The firm had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.24 million. VBI Vaccines had a negative return on equity of 53.12% and a negative net margin of 6,175.95%.

VBIV traded down $0.12 during midday trading on Friday, hitting $2.05. 350,317 shares of the company were exchanged, compared to its average volume of 285,258. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 0.14. VBI Vaccines has a 1-year low of $1.64 and a 1-year high of $5.10.

A number of equities analysts recently issued reports on the company. Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, September 28th. BMO Capital Markets cut their price target on VBI Vaccines from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, July 27th. Finally, ValuEngine raised VBI Vaccines from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. VBI Vaccines currently has a consensus rating of “Hold” and a consensus target price of $8.63.

COPYRIGHT VIOLATION NOTICE: This report was published by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://weekherald.com/2018/11/10/vbi-vaccines-vbiv-issues-earnings-results-misses-estimates-by-0-02-eps.html.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Recommended Story: Moving Average – How it Helps Investors in Stock Selection

Earnings History for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply